Published April 28, 2026 | Version v1
Preprint Open

TLR2/TLR1 Agonist Adjuvant Therapy for Multidrug-Resistant Leprosy

Authors/Creators

  • 1. MedicOath

Description

Synthetic TLR2/TLR1 agonist Pam3CSK4 enhances macrophage and dendritic cell activation through MyD88-dependent NF-κB signaling. This boosts antimicrobial peptide production, nitric oxide synthesis, and Th1 immune responses, compensating for impaired host immunity in multidrug-resistant cases.

Notes

IPFS: QmdRBN3WTXkpT9ULEd3fKG7Jav5Lxxqbbte5RMHVpTcBH5. TX: 0x7aac718b5faa3a3704f79778d9fe4d8b14a75e5b5d84a7ad328b013f37d9e2f2. CC0.

Files

hypothesis.json

Files (325 Bytes)

Name Size Download all
md5:54f526294d8ece65e0071b8487aaae31
325 Bytes Preview Download